ProPhase Labs, Inc. (NASDAQ:PRPH) Sees Large Increase in Short Interest

ProPhase Labs, Inc. (NASDAQ:PRPH) saw a large growth in short interest in January. As of January 15th, there was short interest totalling 116,400 shares, a growth of 19.1% from the December 31st total of 97,700 shares. Based on an average daily volume of 290,200 shares, the short-interest ratio is presently 0.4 days.

Hedge Funds Weigh In On ProPhase Labs

A number of hedge funds have recently made changes to their positions in the stock. HighTower Advisors LLC increased its holdings in ProPhase Labs by 18.3% in the third quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock valued at $434,000 after buying an additional 27,673 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of ProPhase Labs by 9.2% in the third quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock worth $389,000 after buying an additional 13,590 shares during the period. Finally, Sheets Smith Wealth Management acquired a new position in shares of ProPhase Labs in the fourth quarter worth $158,000. Institutional investors and hedge funds own 9.45% of the company’s stock.

ProPhase Labs Price Performance

PRPH traded up $0.00 during midday trading on Monday, reaching $0.27. 15,034,780 shares of the company’s stock were exchanged, compared to its average volume of 1,119,311. ProPhase Labs has a 1-year low of $0.22 and a 1-year high of $7.48. The stock has a market capitalization of $6.37 million, a PE ratio of -0.21 and a beta of -0.36. The business’s 50-day moving average price is $0.64 and its 200 day moving average price is $1.71. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 1.33.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of ProPhase Labs in a research note on Saturday. They set a “sell” rating on the stock.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.